Simplify Logo

Full-Time

Senior Scientist

I/O Discovery

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Mid, Senior

Philadelphia, PA, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD degree in biological sciences (Immunology, Immuno-Oncology, cancer biology) or related field is required.
  • Senior Scientist- PhD +3 years of industry experience.
  • Scientist- PhD + 0-2 years of post PhD experience.
  • In depth knowledge of T cell development, signaling and differentiation/exhaustion is required.
  • Proficiency in conventional immunological techniques such as primary T cell isolation, gene editing/transduction, expansion, ELISA, cell sorting and flow cytometry is required.
  • Experience in CAR-T animal models, in vivo study design and execution is a strong plus.
  • Experience of high-throughput assay development or screening is preferred but not required.
  • Proficiency in single cell transcriptome analysis and data interpretation is a plus.
  • In depth knowledge in topics such as human tumor microenvironment (TME), tumor-infiltrating-lymphocytes (TIL), tertiary lymphoid structures (TLS), Immune Checkpoint Blockade (ICB) is preferred.
  • Knowledge in GVHD and transplant rejection mechanisms is a plus.
  • Innovation in cell therapy space is preferred as evidenced by publications and patents.
  • Language: English
Responsibilities
  • Design and execute CAR-T cell functional assays.
  • Phenotypic analysis of T cell differentiation markers.
  • Handling and engineering human and murine T cells as well as various cancer cells.
  • Analyze and interpret data, troubleshooting, present to and engage cross-functional teams.
  • Stay abreast of the latest advancement of cell therapy in solid tumor. Develop relevant insight in selected disease area.

Legend Biotech develops and sells cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's own cells to combat cancer. Unlike many competitors, Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments. Their goal is to provide effective treatments for hard-to-treat diseases through innovative cell therapy solutions.

Company Stage

IPO

Total Funding

$750.5M

Headquarters

Franklin Township, New Jersey

Founded

2014

Growth & Insights
Headcount

6 month growth

17%

1 year growth

41%

2 year growth

96%
Simplify Jobs

Simplify's Take

What believers are saying

  • Legend Biotech's recent European Commission approval for CARVYKTI® positions it as a leader in the multiple myeloma treatment market.
  • Strategic partnerships, such as the one with MaxCyte, enhance Legend Biotech's capabilities in cell engineering and expand its technological reach.
  • The company's commitment to transparency and investor relations, demonstrated through regular financial updates, fosters investor confidence and long-term stability.

What critics are saying

  • The competitive landscape in cell therapy and personalized medicine is intense, requiring continuous innovation to maintain market position.
  • Regulatory hurdles and the need for extensive clinical trials can delay the commercialization of new therapies, impacting revenue streams.

What makes Legend Biotech unique

  • Legend Biotech's technology-agnostic approach allows it to explore multiple innovative therapies, unlike competitors who may focus on a single technology.
  • The company's comprehensive business model, from discovery to commercialization, ensures control over the entire treatment lifecycle, providing a competitive edge.
  • Legend Biotech's strong focus on CAR-T therapies, particularly for hematological malignancies and solid tumors, sets it apart in the personalized medicine sector.